Table 6.
Characteristics of patients with mantle cell lymphoma receiving allogeneic hematopoietic cell transplants from 1998 to 2007 and registered to the CIBMTR
| Variable | HLA-matched siblings
|
Unrelated
|
||
|---|---|---|---|---|
| N Eval | n (%) | N Eval | n (%) | |
| Age (years) | 525 | 203 | ||
| <50 | 197 (38) | 48 (24) | ||
| 50–59 | 233 (44) | 92 (45) | ||
| 60–69 | 89 (17) | 59 (29) | ||
| ≥70 | 6 (1) | 4 (2) | ||
| Male | 524 | 421 (80) | 203 | 163 (80) |
| Year of transplant | 525 | 203 | ||
| 1998 | 46 (9) | 2 (1) | ||
| 1999 | 58 (11) | 8 (4) | ||
| 2000 | 65 (12) | 15 (7) | ||
| 2001 | 65 (12) | 19 (9) | ||
| 2002 | 43 (8) | 16 (8) | ||
| 2003 | 63 (12) | 28 (14) | ||
| 2004 | 45 (9) | 26 (13) | ||
| 2005 | 63 (12) | 27 (13) | ||
| 2006 | 45 (9) | 35 (17) | ||
| 2007 | 32 (6) | 27 (13) | ||
| Conditioning regimen intensity | 404 | 180 | ||
| Myeloablative | 213 (53) | 84 (47) | ||
| Reduced intensity | 191 (47) | 96 (53) | ||
| Overall survival | 525 | 203 | ||
| 100-days | 85 (81–88) | 78 (72–84) | ||
| 1 year | 65 (61–70) | 53 (46–60) | ||
| 3 years | 54 (50–59) | 37 (30–45) | ||
| Causes of death | 230 | 121 | ||
| Primary disease | 60 (26) | 39 (32) | ||
| New malignancy | 3 (1) | 0 | ||
| GvHD | 31 (13) | 19 (16) | ||
| IPn | 5 (2) | 5 (4) | ||
| Infection | 44 (19) | 12 (10) | ||
| Organ failure | 22 (10) | 21 (17) | ||
| Other causes | 48 (21) | 20 (17) | ||
| Unknown | 17 (7) | 5 (4) | ||
The data presented here are preliminary and were obtained from the Statistical Center of the Center for International Blood and Marrow Transplant Research. The analysis has not been reviewed or approved by the Advisory or Scientific Committee of the CIBMTR.